Sage Journals: Discover world-class research

Abstract

This work describes the production of high–specific activity ⁵⁵Co and the evaluation of the stability of ⁵⁵Co-metal-chelate-peptide complexes in vivo. ⁵⁵Co was produced via the ⁵⁸Ni(p,α)⁵⁵Co reaction and purified using anion exchange chromatography with an average recovery of 92% and an average specific activity of 1.96 GBq/μmol. ⁵⁵Co-DO3A and ⁵⁵Co-NO2A peptide complexes were radiolabeled at 3.7 MBq/μg and injected into HCT-116 tumor xenografted mice. Positron emission tomography (PET) and biodistribution studies were performed at 24 and 48 hours postinjection and compared to those of ⁵⁵CoCl². Both ⁵⁵Co-metal-chelate complexes demonstrated good in vivo stability by reducing the radiotracers’ uptake in the liver by sixfold at 24 hours with ˜ 1% ID/g and at 48 hours with ˜ 0.5% ID/g and reducing uptake in the heart by fourfold at 24 hours with ˜ 0.7% ID/g and sevenfold at 48 hours with ˜ 0.35% ID/g. These results support the use of ⁵⁵Co as a promising new radiotracer for PET imaging of cancer and other diseases.

POSITRON EMISSION TOMOGRAPHY (PET) is a common imaging modality in nuclear medicine. Clinical interest in positron-emitting metals has increased due to their longer half-lives, which are more suitable for radiolabeling macromolecules such as antibodies, peptides, and nanoparticles over traditional PET isotopes such as ¹⁸F, ¹¹C, and ¹⁵O.^1,2 Currently, the most common radiometals used in PET imaging are ⁶⁴Cu, ⁶⁸Ga, ⁸⁹Zr, and ⁸⁶Y, with ⁶⁴Cu, ⁶⁸Ga, and ⁸⁹Zr being used in clinical trials.^3–5 The chemistry of each metal is different, and chelates need to be optimized for the radiometal of interest that will provide stable metal-chelate complexes in vivo.

⁵⁵Co is another isotope of interest for PET imaging. It has a half-life of 17.5 hours, a positron branching ratio of 77%, and an average positron energy of 570 keV, qualities that make it well suited for imaging with peptides, small molecules, and antibodies.^6–11 ⁵⁵CoCl₂ has previously been used clinically to image ischemia in stroke patients^12–15 and in late-onset epileptic seizures¹⁶ due to its ability to mimic calcium uptake. However, it is important to study the preclinical pharmacologic properties of this isotope when it will be incorporated into targeting ligands as imaging agents to probe other diseases. Thus, we investigated the biodistribution of free ⁵⁵CoCl₂ along with the stability of ⁵⁵Co-chelate-peptide complexes in vivo.

⁵⁵Co can be produced via several nuclear reactions, such as ⁵⁸Ni(p,α)⁵⁵Co,^{17–20 56}Fe(p,2n)⁵⁵ ⁵⁵Co,^21,22 and ⁵⁴Fe(d,n) Co.^23,24 The ⁵⁴Fe(d,n)⁵⁵ Co has the highest measured cross section at low energies^8,25; however, ⁵⁴Fe has a low natural abundance. Thus, this target may be cost prohibitive for routine production in most laboratories. The ⁵⁶Fe(p,2n)⁵⁵Co reaction also creates undesirable ⁵⁶Co (via ⁵⁶Fe(p,n)⁵⁶Co), a positron-emitting isotope with a half-life of 77 days that is chemically inseparable from ⁵⁵Co. Additionally, the decay scheme for this isotope yields many high-energy photons. The proton reaction on ⁵⁸Ni has a higher cross section at lower energies than the proton reaction on ⁵⁶Fe,^19,20,22 making it more desirable for low-energy (15 MeV) cyclotrons. This method also produces a small amount of an inseparable side product, ⁵⁷Co (t_1/2 = 271.8 days) at higher energies with a Q value of 8.17 MeV. ⁵⁷Co decays 100% by electron capture and has a low-energy gamma ray of 122 keV. In addition to ⁵⁷Co, this method also produces another side product, ⁵⁷Ni (t_1/2 = 35.6 hours), which can be used as a way to monitor the separation of Co from the starting nickel material by tracking the characteristic gamma rays via gamma spectroscopy.

The production of ⁵⁵Co using ^natNi and ⁵⁸Ni has previously been reported.^11,18,26,27 The specific activity of ⁵⁵Co has been investigated using both ion chromatography of productions using ⁵⁸Ni²⁶, and 4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) titration of productions using ^natNi.²⁷ High-effective specific activity (ESA) of radiometals is important, as metal contaminants have negative impacts on radiolabeling.^28,29, For best radiolabeling results using ⁵⁵Co, ESA measurements must be performed and productions optimized so that high–specific activity material can be obtained.

In this work, we discuss the production of ⁵⁵Co via the ⁵⁸Ni (p,α)⁵⁵Co reaction and report its ESA using both DOTA titrations and ion chromatography.²⁸ We also report the in vivo biodistribution ⁵⁵CoCl₂ and compare it to its ⁵⁵Co-chelate complexes linked to a peptide up to 48 hours. The macrocyclic chelates DOTA and NOTA were chosen because they meet the coordination chemistry required to bind ⁵⁵Co. DOTA and NOTA are commonly attached to peptides via one of their carboxylic acid arms, resulting in DO3A- and NO2A-peptide conjugates, respectively.^30,31 As a model system, we applied Co to a peptide ligand, L19K-FDNB, which has been shown to have long blood-clearance time.³² This property makes this peptide an optimal system for studying the stability of ⁵⁵Co-chelate complexes as ⁵⁵Co-DO3A-L19K-FDNB and ⁵⁵Co-NO2A-L19K-FDNB in vivo at time points up to 48 hours. The biodistribution data for ⁵⁵CoCl₂, ⁵⁵Co-NO2A-L19K-FDNB, and ⁵⁵Co-DO3A-L19K-FDNB were compared at 24 and 48 hours postinjection to establish the in vivo stability of ⁵⁵Co chelated with NO2A- and DO3A-peptide conjugates in tumor-bearing mice.

Materials and Methods

Materials

Trace metal grade reagents were purchased from Sigma-Aldrich (St. Louis, MO) and used without purification, and Milli-Q deionized water (18 MΩ cm⁻¹) was used for all dilutions unless stated otherwise. All glassware and vials were acid washed in 8 M HNO₃ for 24 hours prior to use. DOTA was purchased from Macrocyclics (Dallas, TX). Two versions of the peptide L19K were synthesized by CPC Scientific (Sunnyvale, CA) consisting of the sequence DO3A- or NO2A-PEG_4- GGNECDIARMWEWECFERK-CONH₂, with a Cys-Cys disulfide bridge and polyethylene glycol (PEG) as a spacer between peptide and chelate. ⁵⁸Ni was purchased from Isoflex (San Francisco, CA) with 99.48% isotopic enrichment.

Targetry and Irradiation

Forty-five to 55 mg of ⁵⁸Ni in powder form was plated onto a gold disk by electrodeposition as previously described by McCarthy and colleagues and Szelecsenyi and colleagues.^33,34 The electroplating cell was 9 cm in height, with an inner diameter of 1.8 cm. The bottom of the cell consisted of a Teflon base that connected to the gold disk, exposing a 5 mm circle. A graphite rod was used as the cathode and stirred the solution slowly as a voltage of 2.5 V was applied for ˜ 12 hours. The current remained between 8 and 20 mA throughout the process. Targets were irradiated on a 15 MeV cyclotron (CS-15) for 20 to 60 μAhr and were able to withstand currents up to 30 μA. Targets were allowed to sit for 2 hours prior to processing to allow short-lived contaminants to decay.

Purification

For processing, targets were placed in 10 mL of 9 M HCl and heated with reflux for approximately 1 hour to dissolve the nickel from the gold disk. Once the solution cooled, it was placed in a 1 cm × 10 cm glass column (Bio-Rad, Hercules, CA) with 2.5 g AG1-X8 resin (Bio-Rad). To determine separation conditions, the eluate and 10 to 40 mL of 9 M HCl were collected, followed by another 10 mL of 0.5 M HCl to elute the ⁵⁵Co. Fractions of 1 mL were collected and analyzed using a high-purity germanium (HPGe) detector (Canberra, Meriden, CT), and the final ⁵⁵Co fractions were evaporated to dryness and reconstituted with 20 μL Milli-Q water. ⁵⁵Co productions were analyzed using ion chromatography²⁸ for transition metal contamination.

Effective Specific Activity

DOTA titrations were performed to determine the ESA of ⁵⁵Co productions, and the method was adapted from the 1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) titration method reported previously by McCarthy and colleagues.³³ Then, 1.2 MBq (5 μL) of ⁵⁵Co was added to eight different amounts of DOTA in ammonium acetate pH 5.5, ranging from 4.3 × 10⁻⁴ μmol to 6.3 × 10 μmol. The final volume was brought to 50 μL using 0.5 M ammonium acetate buffer pH 5.5. The solutions were placed in an agitating incubator at 37°C for 30 minutes. Solutions were cooled to room temperature and then centrifuged. A 1 μL aliquot from each DOTA concentration and 1 μL of unbound ⁵⁵Co, for use as a control, were spotted separately onto a silica plate for thin-layer chromatography (TLC) using a 1:1 mixture of 10% w/v ammonium acetate and methanol as the eluent. Plates were analyzed using a Radio TLC Plate Reader (Washington, DC) and analyzed for the percent ⁵⁵Co incorporated into DOTA. Data were plotted as the molar concentration of DOTA versus percent ⁵⁵Co incorporation. The curve was fit using a sigmoid plot fit program in Prism (GraphPad Software, La Jolla, CA). The EC₅₀ value, the concentration of ⁵⁵Co that bound to 50% of the DOTA molecules, was determined from this fit. The ESA was calculated as two times the EC₅₀ value.

Animal Models

All animal care was performed as stated in the Guide for Care and Use for Laboratory Animals by the National Institutes of Health under a protocol approved by the Animal Studies Committee at Washington University in St. Louis. Female athymic Nu/Nu mice (National Cancer Institute, Bethesda, MD) age 6 to 9 weeks were anesthetized with a ketamine/xylazine cocktail (VEDCO, St, Joseph, MO). One hundred microliters of approximately 2 × 10⁷ cell/mL HCT-116 colon cancer cells suspended in saline was subcutaneously injected into the shoulder. Tumors were allowed to grow for 2 weeks before imaging and biodistribution studies.

Small Animal PET/CT imaging

Prior to imaging, animals were anesthetized with 2% isoflurane. One hundred microliters of 74 kBq/μL ⁵⁵CoCl₂ in saline was injected into HCT-116 tumor-bearing mice (n = 4) via tail vein injection and imaged using an Inveon MicroPET/CT scanner (Siemens, Washington, DC) at 2,24, and 48 hours postinjection. Static PET images were acquired for 20 minutes. PET data were reconstructed using standard methods with the maximum a posteriori probability (MAP) algorithm and coregistered with computed tomography (CT) using image display software (Inveon Research Workplace Workstation, Siemens). Volumes of interest (VOI) were drawn using CT anatomic guidelines.

Biodistributions

⁵⁵Co-NO2A-L19K-FDNB and ⁵⁵Co-DO3A-L19K-FDNB were prepared and radiolabeled similarly to the ⁶⁴Cu analogues described by Marquez and colleagues³² and with a final specific activity of 3.7 MBq/μg. One hundred microliters of 74 kBq/μL ⁵⁵CoCl2, 37 kBq/μL ⁵⁵Co-NO2A-FDNB, or 37 kBq/μL ⁵⁵Co-DO3A-FDNB in saline was injected into HCT-116 tumor-bearing mice. For each agent, three mice were sacrificed at 24 and 48 hours postinjection followed by removal of blood, lung, liver, spleen, kidney, muscle, fat, heart, brain, bone, tumor, stomach, small intestine, upper large intestine, and lower large intestine. Each organ was weighed and measured for radioactivity using a gamma counter. The radioactivity was background subtracted, decay corrected to the time of injection, and reported as percent injected dose/g tissue (% ID/g).

Statistical Analysis

All data were analyzed using Prism version 6 and reported as mean ± standard deviation (SD). One-way analysis of variance (ANOVA) was used to calculate p values in order to compare more than two groups with one variable, and p values with a 95% confidence interval (< .05) were considered significant.

Results

Production and Purification of High–Specific Activity 55Co

⁵⁸Ni was plated onto a gold disk with an average efficiency of 95 ± 3% and a thickness of ˜ 300 μm. Irradiations produced an average of 6 ± 1 MBq ⁵⁵Co/μAhr, which is consistent with yields predicted by Kaufman²⁰ and about 30% lower than yields predicted by Reimer and Qaim.¹⁹ ⁵⁷Ni and ⁵⁷Co were coproduced at rates of 16 ± 2 kBq/μAhr and 11 ± 2 kBq/μAhr, respectively, and were approximately 25% and 20% lower than yields predicted by Reimer and Qaim,¹⁹ respectively.

Due to the coproduction of ⁵⁷Ni, separation could be analyzed by measuring the characteristic gamma rays of ⁵⁷Ni (E₁ = 1.378 MeV, I₁ = 81.7% and E₂ = 0.127 MeV, I₂ = 16.7%) and ⁵⁵Co (E₁ = 0.931 MeV, I₁ = 75%; E₂ = 0.477 MeV, I₂ = 20.2%; and E₃ = 1.409 MeV, I₃ = 16.9%) in each fraction using an HPGe detector. Elution profiles for ⁵⁷Ni and ⁵⁵Co are shown in Figure 1. ⁵⁷Co contamination was determined by analyzing its characteristic gamma ray 0.122 MeV (85.6%) in each fraction. Washing the column with an additional 10 to 40 mL 9 M HCl removed nickel without significant loss of ⁵⁵Co. The average recovery of ⁵⁵Co with a 40 mL 9 M HCl column wash was 92 ± 3%.

Figure 1.

Activity of ⁵⁵Co and ⁵⁷Ni in each fraction, as measured using high-purity germanium detection of the characteristic gamma rays, showing good separation.

ESA measured via DOTA titration was found to be 259 MBq/μmol DOTA when washing the column with 10 mL 9 M HCl. Increasing the column wash to 40 mL resulted in an increased ESA of 1.96 GBq/μmol DOTA (Figure 2). Ion chromatography measured nickel concentrations to be 94.6 μmol/MBq and 757 nmol/MBq for 10 mL and 40 mL column washes, respectively. The only radioactive impurity found in the final ⁵⁵Co fraction was ⁵⁷Co at 0.2% of the total ⁵⁵Co activity.

Figure 2.

⁵⁵Co-DOTA titration curves demonstrating a sevenfold increase in ESA (259 MBq/μmol to 1.96 GBq/μmol) when washing the column with an additional 40 mL 9 M HCl acid versus a 10 mL column wash.

55CoCl2 Small Animal PET/CT Imaging and Biodistribution

As an emerging radioisotope applicable in oncologic PET imaging, very few data existed about the in vivo stability of different ⁵⁵Co-chelate complexes. HCT-116 tumor xenografts were imaged (Figure 3A) and post-PET biodistribution studies (Table 1) were performed at 2, 24, and 48 hours postinjection to investigate the distribution of free ⁵⁵CoCl₂ in this model. Interestingly, free ⁵⁵CoCl₂ was observed in the tumor at each of these time points. Tumor to blood ratios at 2 and 48 hours were 0.6 ± 0.1 and 1.9 ± 0.4, respectively (p = .006), exhibiting a threefold increase due to fast blood clearance and relatively slow tumor washout (see Figure 3B and Table 1). High uptake in the heart at 2 hours postinjection could be due to the potential of Co²⁺ to mimic calcium influx.^12,15 Clearance of free ⁵⁵CoCl₂ occurred through the liver and kidney as indicated by the high uptake values at 2 hours postinjection followed by about a twofold consecutive decrease in ⁵⁵CoCl₂ uptake at 24 and 48 hours postinjection (see Table 1).

Figure 3.

A, Twenty-four- and 48-hour PET images of ⁵⁵CoCl₂ showing uptake in the tumor and clearance through the liver, kidney, and intestines. B, The tumor to blood ratio exhibits a threefold increase from 2 to 48 hours.

Table 1.

Biodistribution Data for ⁵⁵CoCl₂, ⁵⁵Co-NO2A-L19K-FDNB, and ⁵⁵Co-DO3A-L19K-FDNB Postinjection

	Postinjection Time
	2 hr (%ID/g ± SD)	24 hr (%ID/g ± SD)			48 hr (%ID/g ± SD)
Organ	A	A	B	C	A	B	C
Blood	4.5 ± 0.6	1.40 ± 0.04	1.57 ± 0.09	1.4 ± 0.2	0.46 ± 0.05	0.63 ± 0.09	0.68 ± 0.04
Lung	4.0 ± 0.3	1.9 ± 0.1	0.9 ± 0.1	0.8 ± 0.1	0.98 ± 0.09	0.46 ± 0.06	0.56 ± 0.03
Liver	15.7 ± 0.4	6.2 ± 0.8	1.0 ± 0.1	1.1 ± 0.2	2.7 ± 0.7	0.44 ± 0.03	0.7 ± 0.1
Spleen	1.9 ± 0.4	0.82 ± 0.05	0.6 ± 0.1	0.56 ± 0.08	0.46 ± 0.04	0.37 ± 0.04	0.35 ± 0.03
Kidney	10.5 ± 1.4	4.4 ± 0.4	12.6 ± 4.1	16.0 ± 3.8	1.9 ± 0.2	2.3 ± 1.0	5.8 ± 1.2
Muscle	0.6 ± 0.1	0.37 ± 0.08	0.31 ± 0.04	0.32 ± 0.09	0.17 ± 0.03	0.15 ± 0.02	0.19 ± 0.04
Fat	1.5 ± 0.9	0.7 ± 0.4	0.8 ± 0.4	0.4 ± 0.1	0.23 ± 0.05	0.3 ± 0.1	0.30 ± 0.03
Heart	4.8 ± 0.4	2.8 ± 0.7	0.7 ± 0.1	0.63 ± 0.06	1.4 ± 0.2	0.33 ± 0.04	0.39 ± 0.03
Brain	0.31 ± 0.02	0.17 ± 0.03	0.08 ± 0.06	0.05 ± 0.01	0.11 ± 0.01	0.02 ± 0.01	0.02 ± 0.01
Bone	1.3 ± 0.2	0.8 ± 0.1	0.28 ± 0.04	0.30 ± 0.04	0.5 ± 0.1	0.14 ± 0.02	0.26 ± 0.05
Tumor	2.8 ± 0.6	1.6 ± 0.2	0.9 ± 0.1	1.1 ± 0.2	0.86 ± 0.08	0.49 ± 0.09	0.71 ± 0.03
Stomach	1.1 ± 0.1	1.0 ± 0.2	0.14 ± 0.05	0.22 ± 0.03	0.5 ± 0.1	0.09 ± 0.04	0.12 ± 0.03
Small intestine	3.6 ± 0.6	1.1 ± 0.2	0.26 ± 0.01	0.31 ± 0.04	0.50 ± 0.04	0.14 ± 0.04	0.19 ± 0.03
Upper large intestine	4.3 ± 0.8	1.5 ± 0.1	0.9 ± 0.1	0.8 ± 0.1	0.7 ± 0.1	0.46 ± 0.06	0.56 ± 0.03
Lower large intestine	1.9 ± 1.0	2.2 ± 0.3	1.0 ± 0.1	1.1 ± 0.2	1.2 ± 0.2	0.44 ± 0.03	0.7 ± 0.1

A = ⁵⁵CoCl₂; B = ⁵⁵Co-NO2A-L19K-FDNB; C = ⁵⁵Co-DO3A-L19K-FDNB.

Stability of 55Co-Chelate Complexes

The stability of radiometal-chelate combinations is crucial when designing new PET imaging probes. Complexes that are not stable in vivo can lead to the radiometal decomplexing from the chelate and accumulating in different organs throughout the body, increasing background signal and dose to nontarget organs. The longer blood clearance associated with the L19K-FDNB peptide that we chose as our model system to investigate ⁵⁵Co allows for the potential decomplexation of ⁵⁵Co-chelate complexes to be measured at clinically relevant time points to evaluate the in vivo stability of these complexes. It has previously been established that changing the radiometal on peptides can have a drastic effect on the affinity of the peptide to its receptor.³⁵ Using ⁵⁵Co to radiolabel the NO2A- or DO3A-peptides dramatically decreased the affinity for their tumor-associated target, vascular endothelial growth factor (VEGF),³² as shown by their reduced tumor uptake compared to the ⁶⁴Cu-labeled analogue, which was radiolabeled at the same specific activity (Figure S1, online version only).

The 24- and 48-hour biodistribution studies of ⁵⁵Co-NO2A-L19K-FDNB and ⁵⁵Co-DO3A-L19K-FDNB were compared to free ⁵⁵CoCl₂ (see Table 1). These data show that both NO2A and DO3A chelates radiolabeled with ⁵⁵Co exhibit good in vivo stability, as shown by their low uptake in the liver, lung, heart, bone, stomach, and small intestine compared to the high uptake of free ⁵⁵CoCl₂ in these organs. The difference in uptake is most notable in the liver, where the ⁵⁵Co-labeled peptides had a sixfold lower uptake than free ⁵⁵CoCl₂ at 24 and 48 hours. ⁵⁵Co-labeled peptides had fourfold lower uptake than free ⁵⁵CoCl₂ in the heart at 24 hours and a sevenfold lower uptake at 48 hours. Although the affinity of this particular peptide was negatively affected by radiolabeling with ⁵⁵Co, this study shows that DOTA- and NOTA-derived chelates form stable complexes with ⁵⁵Co in vivo and may be used to investigate other probes that are insensitive to changes in radiometals.

Discussion

The ⁵⁸Ni(p,α) ⁵⁵Co reaction is an effective route for producing high–specific activity ⁵⁵Co. Previously, this method was reported using a copper disk¹⁸ as opposed to gold; however, using copper as the target backing material could have a negative effect on the ESA as copper has a high affinity to both NOTA and DOTA chelators and would compete with ⁵⁵Co for binding. The downside to this reaction is that it has a lower cross section when compared to other radiometals, such as ⁶⁴Cu and ⁸⁹Zr, which may limit the availability of this isotope to facilities that have solid target cyclotron capabilities.

The biodistribution of ⁵⁵CoCl₂ is comparable to that previously observed for ⁶⁴CuCl₂, as both metals are divalent cations and may have similar interactions with transport proteins in vivo.^36–40 The tumor uptake of ⁵⁵Co is interesting and warrants further investigation. It is possible that its uptake is due to the overexpression of calcium ion channels often found in cancer cells.⁴¹ Several studies have shown the uptake of ⁵⁵CoCl₂ in ischemic cells, and this is believed to be due to ⁵⁵Co partially mirroring calcium influx.^12,15

The in vivo stability of the NOTA and DOTA analogues, NO2A and DO3A, complexed with ⁵⁵Co provides the foundation for developing ⁵⁵Co-labeled peptides, antibodies, nanoparticles, and small molecules. ⁵⁵Co-NOTA and ⁵⁵Co-DOTA complexes have significantly lower liver uptake when compared to ⁶⁴Cu-NOTA and ⁶⁴Cu-DOTA complexes (see Table 1),^7,42 which could be beneficial in cases where reduced background signal is desired; that is, liver metastases. The lower liver uptake observed with the ⁵⁵Co complexes implies that the transchelation problem that exists with ⁶⁴Cu^42–44 is greatly reduced with the use of ⁵⁵Co. This reduction in transchelation for the cobalt complexes is in agreement with the transfer half-life of 800 hours for Co from Co(DOTATOC) in human blood serum measured by Heppeler and colleagues.⁷ Additionally, the high positron branching ratio (four times that of ⁶⁴Cu and three times that of ⁸⁹Zr) leads to similar images with a lower amount of radioactivity administered. One drawback, however, is the higher dose to nontarget tissue from the additional gamma rays present from the decay of ⁵⁵Co.

Since the affinity of some peptides is dependent on the attached radiometal, it would be interesting to examine this effect on different peptide models. The anti-VEGF peptide used in this work exhibited lower tumor uptake than previously measured with ⁶⁴Cu (see Figure S1, online version only); however, in work done by Heppeler and colleagues, ⁵⁵Co-DOTATOC showed higher affinity for the somatostatin type 2 receptor than any other radiometals measured.⁷ These different studies imply that ⁵⁵Co may also coordinate with the peptide probe concurrently with the chelate to elicit a change in the peptide's affinity for its target. Therefore, determining the structure-activity relationship of these peptide-chelate-metal complexes would be significant for designing superior PET imaging probes.

Conclusions

⁵⁵Co can be made with high specific activity via the ⁵⁸Ni(p,α)⁵⁵Co reaction. The in vivo stability of ⁵⁵Co-labeled NOTA and DOTA derivatives makes this radioisotope a promising isotope for many different applications. Future work should compare the affinity of ⁵⁵Co-labeled peptides to other radiometals to optimize the best metal-chelate-peptide combination for the application.

Footnotes

Acknowledgments

We would like to acknowledge Patricia Margenau and Bill Margenau for operation of the CS15 cyclotron. The studies presented in this work were conducted in the MIR Pre-Clinical Pet-CT Facility of the Washington University School of Medicine.

Financial disclosure of authors: This work was performed with support from the Siteman Cancer Center Small Animal Imaging Core under grant number P30 CA91842. This work was supported in part by Department of Energy grant number DESC0007352.

Financial disclosure of reviewers: None reported.

References

Ikotun

Lapi

. The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86. Future Med Chem 2011;3:599–621, doi:10.4155/fmc.1 1.14.

Brasse

Nonat

. Radiometals: towards a new success story in nuclear imaging?. Dalton Trans 2015;44:4845–58, doi:10.1039/c4dt02911a.

Anderson

Ferdani

. Copper-64 radiopharmaceuticals for PET imaging of cancer: advances in preclinical and clinical research. Cancer Biother Radiopharm 2009;24:379–93, doi:10.1089/cbr. 2009.0674.

Dijkers

Oude Munnink

Kosterink

. Biodistribution of 89 Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010;87:586–92, doi:10.1038/clpt.2010.12.

Ambrosini

Campana

Bodei

. ⁶⁸Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 2010;51:669–73, doi:10.2967/jnumed.109.071712.

Mirzaii

Kakavand

Talebi

Rajabifar

. Electrodeposition iron target for the cyclotron production of Co-55 in labeling proteins. J Radioanalyt Nucl Chem 2012;292:261–7, doi:10.1007/s10967-011-1399-x.

Heppeler

Andre

Buschmann

. Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chemistry 2008;14:3026–34, doi:10.1002/chem.200701264.

Thisgaard

Olesen

Dam

. Radiosynthesis of Co-55- and Co-58m-labelled DOTATOC for positron emission tomography imaging and targeted radionuclide therapy. J Labelled Comp Radiopharm 2011;54:758–62, doi:10.1002/jlcr.1919.

Goethals

Volkaert

Vandewielle

. Co-55-EDTA for renal imaging using positron emission tomography (PET): a feasibility study. Nucl Med Biol 2000;27:77–81, doi:10.1016/S0969-8051(99)00077-3.

10.

Karanikas

Schmaljohann

Rodrigues

. Examination of Co-complexes for radiolabeling of platelets in positron emission tomographic studies. Thromb Res 1999;94:111–5, doi:10.1016/S0049-3848(98)00204-7.

11.

Ferreira

Lapi

Steele

. ⁵⁵Cobalt complexes with pendant carbohydrates as potential PET imaging agents. Appl Radiat Isot 2007;65:1303–8, doi:10.1016/j.apradiso.2007.06.003.

12.

De Reuck

Santens

Keppens

. Cobalt-55 positron emission tomography in recurrent ischaemic stroke. Clin Neurol Neurosurg 1999;101:15–8, doi:10.1016/S0303-8467(98)00076-6.

13.

Stevens

Jansen

HML

De Reuck

. ⁵⁵Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI. J Neurol Sci 1999;171:11–8, doi:10.1016/S0022-510X(99)00229-4.

14.

De Reuck

Santens

Strijckmans

Lemahieu

. European Task Force on Age-Related White Matter Changes. Cobalt-55 positron emission tomography in vascular dementia: significance of white matter changes. J Neurol Sci 2001;193:1–6, doi:10.1016/S0022-510X(01)00606-2.

15.

De Reuck

Stevens

Jansen

. The significance of cobalt-55 positron emission tomography in ischemic stroke. J Stroke Cerebrovasc Dis 1999;8:17–21, doi:10.1016/S1052-3057(99)80034-2.

16.

De Reuck

Vonck

Santens

. Cobalt-55 positron emission tomography in late-onset epileptic seizures after thrombo-embolic middle cerebral artery infarction. J Neurol Sci 2000;181:13–8, doi:10.1016/S0022-510X(00)00382-8.

17.

Brinkman

Helmer

Lindner

. Nickel and copper foils as monitors for cyclotron beam intensities. Radiochem Radioanalyt Lett 1977;28:9–19.

18.

Spellerberg

Reimer

Blessing

. Production of ⁵⁵Co and ⁵⁷Co via proton induced reactions on highly enriched ⁵⁸Ni. Appl Radiat Isot 1998;49:1519–22, doi:10.1016/S0969-8043(97)10119-1.

19.

Reimer

Qaim

. Excitation functions of proton induced reactions on highly enriched Ni-58 with special relevance to the production of Co-55 and Co-57. Radiochim Acta 1998;80: 113–20, doi:10.1524/ract.1998.80.3.113.

20.

Kaufman

. Reactions of protons with 58-nickel and 60-nickel. Phys Rev 1960;117:1532–8, doi:10.1103/PhysRev.117.1532.

21.

Al-Abyad

Comsan

Qaim

. Excitation functions of proton-induced reactions on ^natFe and enriched ⁵⁷Fe with particular reference to the production of 57Co. Appl Radiat Isot 2009;67:122–8, doi:10.1016/j.apradiso.2008.07.006.

22.

Jenkins

Wain

. Excitation functions for bombardment of Fe-56 with protons. J Inorgan Nucl Chem 1970;32:1419–1425, doi:10.1016/0022-1902(70)80628-5.

23.

Sharma

Zweit

Smith

Downey

. Production of cobalt-55, a short-lived, positron emitting radiolabel for bleomycin. Appl Radiat Isot 1986;37:105–9, doi:10.1016/0883-2889(86)90055-9.

24.

Coetzee

Peisach

. Activation cross-sections for deuteron-induced reactions on some elements of first transition series, up to 5.5 MeV. Radiochim Acta 1972;17:1–6, doi:10.1524/ract.1972.17.1.

25.

Zavorka

Simeckova

Honusek

Katovsky

. The activation of Fe by deuterons at energies up to 20 MeV. J Korean Phys Soc 2011;59:1961–4, doi:10.3938/jkps.59.1961.

26.

Mastren

Sultan

Lapi

. Production and separation of Co-55 via the Ni-58(p,alpha)Co-55 reaction. AIP Conf Proc 2012;1509: 96–100, doi:10.1063/1.4773948.

27.

Valdovinos

Graves

Barnhart

Nickles

. Co-55 separation from proton irradiated metallic nickel. AIP Conf Proc 2014;1626: 217–20, doi:10.1063/1.4901397.

28.

Mastren

Guthrie

Eisenbeis

. Specific activity measurement of (6)(4)Cu: a comparison of methods. Appl Radiat Isot 2014;90:117–21, doi:10.1016/j.apradiso.2014.03.016.

29.

Zeng

Anderson

. Rapid and sensitive LC-MS approach to quantify non-radioactive transition metal impurities in metal radionuclides. Chem Commun (Camb) 2013;49:2697–9, doi:10.1039/c3cc39071c.

30.

De Leon-Rodriguez

Kovacs

. The synthesis and chelation chemistry of DOTA-peptide conjugates. Bioconjug Chem 2008; 19:391–402, doi:10.1021/bc700328s.

31.

Studer

Meares

. Synthesis of novel 1,4,7-triazacyclononane-N,N′,N″triacetic acid derivatives suitable for protein labeling. Bioconjug Chem 1992;3:337–41, doi:10.1021/bc00016a013.

32.

Marquez

Ikotun

Meares

Lapi

. Development of a radiolabeled irreversible peptide (RIP) as a PET imaging agent for vascular endothelial growth factor. J Labelled Comp Radiopharm 2013;56:1029–1034, doi:10.2967/jnumed.113.130898.

33.

McCarthy

Shefer

Klinkowstein

. Efficient production of high specific activity Cu-64 using a biomedical cyclotron. Nucl Med Biol 1997;24:35–43, doi:10.1016/S0969-8051(96)00157-6.

34.

Szelecsenyi

Blessing

Qaim

. Excitation-functions of proton-induced nuclear-reactions on enriched Ni-61 and Ni-64—possibility of production of no-carrier-added Cu-61 and Cu-64 at a small cyclotron. Appl Radiat Isot 1993;44:575–80, doi:10.1016/0969-8043(93)90172-7.

35.

Ginj

Maecke

. Radiometals of interest for peptide labeling and labeling approaches. In: Sigel

, editor. Metal ions in biological systems. Volume 42: Metal complexes in tumor diagnosis and as anticancer agents. New York: CRC Press; 2004, 116–123.

36.

Jorgensen

Persson

Madsen

Kjaer

. High tumor uptake of Cu-64: implications for molecular imaging of tumor characteristics with copper-based PET tracers. Nucl Med Biol 2013;40:345–50, doi:10.1016/j.nucmedbio.2013.01.002.

37.

Zhang

Cai

. Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer. Acad Radiol 2011;18:1561–8, doi:10.1016/j.acra.2011.08.006.

38.

Qin

Liu

Chen

. Theranostics of malignant melanoma with (CuCl2)-Cu-64. J Nucl Med 2014;55:812–7, doi:10.2967/jnumed.113.133850.

39.

Kim

Jang

Park

. Detection of increased Cu uptake by human copper transporter 1 gene overexpression using PET with ⁶⁴CuCl₂ in human breast cancer xenograft model. J Nucl Med 2014;55:1692–8, doi:10.2967/jnumed.114.141127.

40.

Peng

Lutsenko

Sun

Muzik

. Positron emission tomography of copper metabolism in the Atp7b(—/—) knock-out mouse model of Wilson's disease. Mol Imaging Biol 2012;14: 70–8, doi:10.1007/s11307-011-0476-4.

41.

Xiong

Z-G

. Ion channels as targets for cancer therapy. Int J Physiol Pathophysiol Pharmacol 2011;3:156–66.

42.

Zhang

Hong

Engle

. Positron emission tomography imaging of CD105 expression with a ⁶⁴Cu-labeled monoclonal antibody NOTA is superior to DOTA. Plos One 2011;6: e28005, doi:10.1371/journal.pone.0028005.

43.

Kumar

Gallazzi

Ferdani

. In vitro and in vivo evaluation of ⁶⁴Cu-radiolabeled KCCYSL peptides for targeting epidermal growth factor receptor-2 in breast carcinomas. Cancer Biother Radiopharm 2010;25:693–703, doi:10.1089/cbr.2010.0820.

44.

Bass

Wang

Welch

Anderson

. In vivo transchelation of copper-64 from TETA-octreotide to superoxide dismutase in rat liver. Bioconjug Chem 2000;11:527–32, doi:10.1021/bc990167l.

Cyclotron Production of High–Specific Activity 55 Co and In Vivo Evaluation of the Stability of 55 Co Metal-Chelate-Peptide Complexes

Abstract

Materials and Methods

Materials

Targetry and Irradiation

Purification

Effective Specific Activity

Animal Models

Small Animal PET/CT imaging

Biodistributions

Statistical Analysis

Results

Production and Purification of High–Specific Activity 55Co

55CoCl2 Small Animal PET/CT Imaging and Biodistribution

Stability of 55Co-Chelate Complexes

Discussion

Conclusions

Footnotes

Acknowledgments

References